Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Prostate-specific membrane antigen PET: Who should undergo advanced imaging?

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.02.20
Views: 270

Dr Jérémie Calais - David Geffen School of Medicine UCLA, Los Angeles, USA

Dr Jérémie Calais speaks to ecancer at ASCO GU 2020 in San Francisco about prostate-specific membrane antigen (PSMA) PET/CT imaging.

He explains the various indications associated with this imaging tool and the assessment of high-risk patients.

He also states that the detection of pelvic nodal disease is not entirely accurate, as some cases may be missed - and how this needs to be considered in the management of metastatic patients.

Dr Calais also discusses the implementation of this type of advanced imaging, which is used worldwide. However, he states that currently, there is no approved PSMA-PET agent approved in the US.

Related videos

follow us

Biosimilar Medicines Core Principles and Communication

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation